Articles related to MYELOMA

A 0.25-credit, 15-minute video CME program that asks the question, “How do you decide which multiple myeloma treatment regimen is best?” Hear what the presenters have to say.

The future certainly looks bright for patients diagnosed with multiple myeloma, as this opinion piece points out, thanks to combination therapies partnered with easily available, reliable minimal residual disease (MRD) assays. How close are we to a functional cure?

Dr. Mohyudding summarizes key findings ASCO reports, including updates on teclistamab in CAR-T, the DETERMINATION trial assessing auto-transplantation, cilta-cel (covered by HCN here), and the ATLAS study evaluating carfilzomib with lenalidomide and dexamethasone as maintenance vs. lenalidomide alone.

This report provides longer-term results from the CARTITUDE-1 trial of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma. This update covers 97 patients at a median follow up of ~28 months. The overall response rate was 97.9%, with an 82% stringent complete response across both standard and high-risk subgroups. These longer-term data from CARTITUDE-1 in triple-class exposed patients with RRMM demonstrate deep and durable responses to cilta-cel over time, including in high-risk subgroups.

Data from a large phase III trial (Myeloma XI) were examined to determine the relationship between MRD status, PFS, and OS in post-ASCT patients randomly assigned to lenalidomide maintenance or no maintenance at 3 months after ASCT. At ASCT + 3 and ASCT + 9, MRD-negative status was associated with improved PFS and OS. Sustained MRD negativity from ASCT + 3 to ASCT + 9 or the conversion to MRD negativity by ASCT + 9 was associated with the longest PFS/OS.

In an editorial accompanying the final results of the TOURMALINE-MM1 study, Drs. D’Souza and Lonial question whether overall survival (OS) is “still the gold standard for demonstrating the value of a novel agent in phase III trials early in the disease course given the current treatment landscape.”